Nuveen
ARCT icon

Nuveen’s Arcturus Therapeutics ARCT Stock Holding History

Nuveen’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-51,200
Closed -$1K – 3249
2022
Q1 		$1K Buy
+51,200
New +$1.31M ﹤0.01% 3376
2021
Q4 		– Sell
-51,200
Closed -$3K – 3323
2021
Q3 		$3K Buy
+51,200
New +$2.29M ﹤0.01% 3400
2021
Q2 		– Sell
-102,200
Closed -$4K – 3360
2021
Q1 		$4K Hold
102,200
– – ﹤0.01% 3338
2020
Q4 		$4K Buy
+102,200
New +$6.92M ﹤0.01% 3278

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Nuveen's ARCT Position: Q2 2026 in Review

Nuveen held its Arcturus Therapeutics (ARCT) position steady in Q2 2026 at 52,542 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #3443.

Nuveen first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. The position peaked at $6.14M in Q4 2023. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Nuveen held 52,542 shares of Arcturus Therapeutics worth $353K as of Q2 2026.
  • Nuveen left its Arcturus Therapeutics share count unchanged in Q2 2026.
  • Arcturus Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3443 holding.
  • Nuveen first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Nuveen's Arcturus Therapeutics position peaked at $6.14M in Q4 2023.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.